Fig. 6: Drug treatment protection from LPS-induced inflammation in iMGLs.
From: Genetic contribution to microglial activation in schizophrenia
a IL6 (H(2) = 0.9800, p = 0.6500), IL8 (H(2) = 1.8600, p = 0.4163) and MCP1 (H(2) = 1.220, p = 0.5824) secretion after 24-h 100 ng/ml LPS treatment between the groups. Kruskal–Wallis test. b LPS effect on pHrodo-zymosan phagocytosis after 24-h LPS treatment and 6 h after adding pHrodo bioparticles (CTRL: H(4) = 3.397, p = 0.4937; ST: H(4) = 3.094, p = 0.5422; HT: H(4) = 2.592, p = 0.6282). Kruskal–Wallis test. c IL6 (χ2(4) = 5.400, p = 0.1514), IL8 (χ2(4) = 6.360, p = 0.0933), MCP1 (χ2(4) = 3.480, p = 0.3720) and TNFα (χ2(4) = 3.735, p = 0.3141) secretion in CTRL iMGL cultures after 30 min pre-treatment with 10 µM clozapine, 10 µM minocycline or 5 µM sulforaphane and 24-h 100 ng/ml LPS treatment. Friedman test, n = 5 lines.
